- Home
- IDR vs PBYI Comparison
IDR vs PBYI Comparison
Compare IDR & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDR
- PBYI
- Stock Information
- Founded
- IDR 1996
- PBYI 2010
- Country
- IDR United States
- PBYI United States
- Employees
- IDR N/A
- PBYI N/A
- Industry
- IDR Precious Metals
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- IDR Basic Materials
- PBYI Health Care
- Exchange
- IDR Nasdaq
- PBYI Nasdaq
- Market Cap
- IDR 180.8M
- PBYI 171.7M
- IPO Year
- IDR N/A
- PBYI N/A
- Fundamental
- Price
- IDR $19.90
- PBYI $3.28
- Analyst Decision
- IDR Strong Buy
- PBYI Strong Buy
- Analyst Count
- IDR 1
- PBYI 1
- Target Price
- IDR $17.50
- PBYI $7.00
- AVG Volume (30 Days)
- IDR 628.1K
- PBYI 351.2K
- Earning Date
- IDR 08-05-2025
- PBYI 08-07-2025
- Dividend Yield
- IDR N/A
- PBYI N/A
- EPS Growth
- IDR 144.40
- PBYI 143.51
- EPS
- IDR 0.62
- PBYI 0.77
- Revenue
- IDR $27,144,971.00
- PBYI $232,709,000.00
- Revenue This Year
- IDR $9.76
- PBYI N/A
- Revenue Next Year
- IDR N/A
- PBYI N/A
- P/E Ratio
- IDR $32.09
- PBYI $4.25
- Revenue Growth
- IDR 67.42
- PBYI 2.68
- 52 Week Low
- IDR $9.58
- PBYI $2.23
- 52 Week High
- IDR $21.96
- PBYI $4.13
- Technical
- Relative Strength Index (RSI)
- IDR 70.28
- PBYI 40.98
- Support Level
- IDR $19.13
- PBYI $3.34
- Resistance Level
- IDR $21.96
- PBYI $3.55
- Average True Range (ATR)
- IDR 1.27
- PBYI 0.13
- MACD
- IDR 0.30
- PBYI -0.02
- Stochastic Oscillator
- IDR 78.44
- PBYI 11.11
About IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.